Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial

Genetic data implicate IL-33 in asthma susceptibility. Itepekimab, a monoclonal antibody targeting IL-33, demonstrated clinical activity in asthma, with potential in chronic obstructive pulmonary disease (COPD). In this study we first aimed to test the hypothesis that genetic variants in the IL-33 p...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	The lancet respiratory medicine 2021-11, Vol.9 (11), p.1288-1298
Hauptverfasser:	Rabe, Klaus F, Celli, Bartolome R, Wechsler, Michael E, Abdulai, Raolat M, Luo, Xiaodong, Boomsma, Maarten M, Staudinger, Heribert, Horowitz, Julie E, Baras, Aris, Ferreira, Manuel A, Ruddy, Marcella K, Nivens, Michael C, Amin, Nikhil, Weinreich, David M, Yancopoulos, George D, Goulaouic, Helene
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!